Treatment of primary CLL cells with bezafibrate and medroxyprogesterone acetate induces apoptosis and represses the pro-proliferative signal of CD40-ligand, in part through increased 15dDelta12,14,PGJ2.
D017209:Apoptosis / Q000187:drug effects*; D001629:Bezafibrate / Q000494:pharmacology*; D023201:CD40 Ligand / Q000037:antagonists & inhibitors*; D049109:Cell Proliferation / Q000187:drug effects; D004338:Drug Combinations; D004357:Drug Synergism; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000473:pathology; D017258:Medroxyprogesterone Acetate / Q000494:pharmacology*; D024101:Mitochondrial Proteins; D015230:Prostaglandin D2 / Q000819:agonists / Q000031:analogs & derivatives*; D017382:Reactive Oxygen Species; D015398:Signal Transduction; D013481:Superoxides; D014407:Tumor Cells, Cultured
C097240:15-deoxy-delta(12,14)-prostaglandin J2; D004338:Drug Combinations; D024101:Mitochondrial Proteins; D017382:Reactive Oxygen Species; D013481:Superoxides; D023201:CD40 Ligand; D017258:Medroxyprogesterone Acetate; D015230:Prostaglandin D2; D001629:Bezafibrate